Literature DB >> 11340387

Ocular attacks after phacoemulsification and intraocular lens implantation in patients with Behçet disease.

T Matsuo1, M Takahashi, Y Inoue, K Egi, Y Kuwata, A Yamaoka.   

Abstract

PURPOSE: To elucidate factors related to ocular inflammatory attacks after cataract surgery, limited to a single procedure of phacoemulsification and intraocular lens implantation, in patients with Behçet disease.
METHODS: This retrospective study included 12 consecutive patients (16 eyes) with Behçet disease, who underwent phacoemulsification and intraocular lens implantation during 4 years from January 1995 to December 1998 at three institutions. Their medical records were reviewed, and factors related to the ocular attacks were analyzed.
RESULTS: Four eyes of 3 patients experienced ocular attacks during 1 year before cataract surgery, while 4 eyes of 4 patients developed ocular attacks during 1 year after the surgery. The development of ocular attacks after cataract surgery was significantly related with the presence of ocular attacks during 1 year before the surgery (p = 0.0286, chi(2) test). The patients' age or gender, the duration of Behçet disease or oral medications for Behçet disease did not show any relationship with the presence or absence of ocular attacks after cataract surgery. The visual acuity improved in all patients after the surgery, including those who developed ocular attacks.
CONCLUSIONS: The experience of ocular attacks during 1 year before cataract surgery is related to postoperative ocular attacks. Despite postoperative ocular attacks, phacoemulsification with intraocular lens implantation is a safe procedure to expect a good visual outcome in patients with Behçet disease. Copyright 2001 S. Karger AG, Basel

Entities:  

Mesh:

Year:  2001        PMID: 11340387     DOI: 10.1159/000050854

Source DB:  PubMed          Journal:  Ophthalmologica        ISSN: 0030-3755            Impact factor:   3.250


  9 in total

1.  Intraocular surgery under systemic interferon-alpha therapy in ocular Adamantiades-Behçet's disease.

Authors:  Lothar Krause; Andreas Altenburg; Nikolaos E Bechrakis; Gregor Willerding; Christos C Zouboulis; Michael H Foerster
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2007-04-13       Impact factor: 3.117

2.  Cataract surgery in uveitis.

Authors:  Rupesh Agrawal; Somashiela Murthy; Sudha K Ganesh; Chee Soon Phaik; Virender Sangwan; Jyotimai Biswas
Journal:  Int J Inflam       Date:  2012-02-08

Review 3.  Decision-making and management of uveitic cataract.

Authors:  Nicole Shu-Wen Chan; Seng-Ei Ti; Soon-Phaik Chee
Journal:  Indian J Ophthalmol       Date:  2017-12       Impact factor: 1.848

4.  Behcet's Disease Presenting With Bilateral Hypopyon Masquerading Post Cataract Surgery Endophthalmitis.

Authors:  Mehrdad Mohammadpour; Meysam Kosari; Masoud Khorrami-Nejad
Journal:  Int Med Case Rep J       Date:  2019-11-28

5.  New insights into cataract surgery in patients with uveitis: A detailed review of the current literature.

Authors:  Rakan S Al-Essa; Abdullah M Alfawaz
Journal:  Saudi J Ophthalmol       Date:  2022-02-18

Review 6.  [Current cataract surgery for uveitis in childhood].

Authors:  A Heiligenhaus; P Szurman; C Heinz
Journal:  Ophthalmologe       Date:  2007-07       Impact factor: 1.174

7.  Comprehensive analysis of vitreous specimens for uveitis classification: a prospective multicentre observational study.

Authors:  Kazuichi Maruyama; Tohru Inaba; Sunao Sugita; Ryo Ichinohasama; Kenji Nagata; Shigeru Kinoshita; Manabu Mochizuki; Toru Nakazawa
Journal:  BMJ Open       Date:  2017-11-16       Impact factor: 2.692

8.  Phacoemulsification in patients with uveitis: long-term outcomes.

Authors:  Serdar Ozates; Nilufer Berker; Pinar Cakar Ozdal; Yasemin Ozdamar Erol
Journal:  BMC Ophthalmol       Date:  2020-03-17       Impact factor: 2.209

9.  Vitreous lavage fluid and bronchoalveolar lavage fluid have equal diagnostic value in sarcoidosis.

Authors:  Kazuichi Maruyama; Tohru Inaba; Tsutomu Tamada; Toru Nakazawa
Journal:  Medicine (Baltimore)       Date:  2016-12       Impact factor: 1.817

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.